Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Projected Long-Term Survival High for Patients with Advanced Non–Small-Cell Lung Cancer Treated with Pembrolizumab

TOP - May 2017, Vol 10, No 2 - Lung Cancer
Chase Doyle

Orlando, FL—Durability of benefit (ie, the possibility for sustained remission in patients with previously incurable disease) is already one of the hallmarks of immunotherapy. According to a recent statistical analysis, however, this durability even exceeded expectations.

Based on data from multiple KEYNOTE clinical trials, Matthew D. Hellmann, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, estimates that ≤25% of patients with advanced non–small-cell lung cancer who received pembrolizu­mab will achieve long-term survival. When compared with a long-term survival rate of just 3% to 4% for patients who received chemotherapy, these findings underscore the “remarkable step forward” made with immunotherapy, Dr Hellmann noted.

“We’re cautious to use these sorts of words, but these outcomes really do start to approach the concept of cure for patients with advanced cancer. These aren’t just numbers on a curve or dots on a plot; these are patients that we see in the clinic who are continuing to do well years after being given pembrolizumab,” he said.

As Dr Hellmann reported at the 2017 Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, whereas cytotoxic chemotherapy or tyrosine inhibitors provide some meaningful anticancer responses, progression invariably occurs. With the advent of immunotherapies, however, the survival curve for patients with several types of advanced cancers has fundamentally changed.

“Using conventional modeling, in which we assume that everyone progresses, the proportion of patients with long-term survival is potentially zero. In the context of immunotherapy, however, progression and death is not necessarily inevitable, and long-term survival models must consider the possibility of a plateaued survival when estimating outcomes further out,” said Dr Hellmann.

Using medium-term survival data from KEYNOTE-001 and KEYNOTE-010 studies, in which previously treated patients with PD-L1–positive non–small-cell lung cancer were given pembrolizumab, the investigators projected the percentage of patients who would achieve long-term survival.

“Our approach was to take an initial estimate of long-term survival in patients treated in KEYNOTE-001 and then independently examine data from KEYNOTE-010 to validate the reproducibility of that estimate,” Dr Hellmann explained.

With this model, based on KEYNOTE-001 data, it was estimated that approximately 25.4% of patients receiving pembrolizumab therapy would survive long-term. Further analysis of KEYNOTE-010 cutoff data, which included 6 additional months of patient follow-up, showed a long-term survival estimate of approximately 21.5%. By contrast, docetaxel chemotherapy has an estimated long-term survival rate of 3% to 4% in the same patient population.

“The lives and the expectations of these patients has remarkably changed,” said Dr Hellmann, who emphasized that this is just the beginning of research into immunotherapy’s survival benefit.

“We’ve got a lot of work to do in understanding with precision who these people are in the tail of the curve so that we can get them the right therapy from the start,” he concluded.

Related Items
Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression
Web Exclusives published on May 26, 2020 in FDA Updates, Lung Cancer
Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC
Web Exclusives published on May 18, 2020 in FDA Updates, Lung Cancer
First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML
Chase Doyle
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in Value-Based Care
Tazemetostat Demonstrates Antitumor Activity in Relapsed/Refractory Follicular Lymphoma
Chase Doyle
TOP - March 2020, Vol 13, No 2 published on March 11, 2020
Ceritinib Effective in Treating Brain Metastases in NSCLC
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in Lung Cancer
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
Web Exclusives published on February 4, 2020 in FDA Updates, In the News, Lung Cancer, Thyroid Cancer
Osimertinib Superior TKI as First-Line Treatment of Advanced NSCLC with EGFR Mutation
Phoebe Starr
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Lung Cancer
Nivolumab plus Ipilimumab Combination Improves Survival in Patients with Metastatic NSCLC
Phoebe Starr
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Lung Cancer
Delivering High-Value Personalized Interventions
Chase Doyle
Web Exclusives published on December 9, 2019 in Clinical Pathways
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
Web Exclusives published on November 25, 2019 in Lung Cancer
Last modified: April 27, 2020